Vitamin D may protect the Alzheimer's brain through 5 pathways at once - review 2026

Vitamin D in Alzheimer's disease: Neuroinflammatory, metabolic, and clinical implications

Journal of Alzheimer's Disease, 2026, https://doi.org/10.1177/13872877261460850 PDF behind paywall

Mohd Kashif, Man-Hau Ho, Ashok Kumar Pandurangan, Mohammad Waseem, Dhriti Majumder, Szu-Yi Chou (handling editor: William Grant)

Summary by Claude - June 2026

This is a narrative review (peer-reviewed; Journal of Alzheimer's Disease, Sage/IOS Press) that pulls together molecular, cell, animal, and human evidence on how vitamin D may act in Alzheimer's disease (AD). Its value is the integration: rather than treating one mechanism, it links five disease pathways vitamin D appears to touch — amyloid-β clearance, calcium dysregulation, oxidative stress/mitochondrial function, neuroinflammation, and brain insulin resistance ("type 3 diabetes").

Practical takeaway. The human signal is consistent but observational. A 12,388-person analysis found vitamin D supplement users had 40% lower dementia risk (HR 0.60, 95% CI 0.55–0.65), varying by sex and APOE ε4 status. The Cardiovascular Health Study found severe deficiency (<25 nmol/L) more than doubled AD/all-cause dementia risk, with risk rising sharply below 50 nmol/L. A 2023 meta-analysis put low D (<25 ng/mL) at pooled HR 1.59 for AD. The review cites ~30–50 ng/mL (75–125 nmol/L) as the range linked to better outcomes.

Mechanisms (mostly preclinical). Vitamin D readily crosses the blood-brain barrier; neurons and glia express VDR and CYP27B1, so the brain makes its own calcitriol. In animal/cell models, vitamin D enhanced microglial Aβ phagocytosis, upregulated P-glycoprotein and LRP1 to push Aβ out across the BBB, stabilized calcium handling, activated the Nrf2/PGC-1α/SIRT3 antioxidant axis, and shifted microglia to an anti-inflammatory state (suppressing NLRP3/NLRP1 inflammasomes, lowering IL-6/TNF-α, raising IL-10). VDR polymorphisms (FokI, BsmI, ApaI, TaqI, Cdx2) are flagged as possible risk modifiers.

The honest counter-evidence. The review preserves a dissenting result: in APP/PS1 mice, serum D stayed low despite adequate intake (deficiency as a consequence of AD), and supplementation increased Aβ deposition via a non-genomic VDR/p53 pathway (Lai 2022). Direction of causation is genuinely unresolved — the authors call the D–AD link plausibly bidirectional.

Dosing note. Human intervention data are thin and mixed. A 12-month RCT of just 800 IU/day improved cognition and lowered plasma Aβ/BACE-1 in AD patients; weekly 50,000 IU raised plasma Aβ (read as improved clearance) in deficient adults; memantine + D beat either alone in small trials. The review echoes the Grant/Vieth critique that trials using fixed doses without targeting achieved 25(OH)D likely underestimate the true effect.

What this does NOT show / limitations. Narrative review, not systematic — no pooled effect size of its own, and study selection isn't protocol-driven. The mechanistic weight is animal and in-vitro; several strong effects come from injected calcitriol (1,25(OH)₂D), which is not how people supplement and carries hypercalcemia risk. Human data are overwhelmingly observational, so reverse causation and confounding (sun, activity, general health) aren't ruled out. No co-factor protocol (magnesium, K2) is addressed. Bottom line the authors themselves draw: treat vitamin D as a complementary/preventive modulator, not a standalone AD therapy.


Related in VitaminDWiki

Other things the INCREASE the Risk

Other things that REDUCE the risk

Treat Alzheimer's - along with Vitamin D

End of Alzheimer's

Tags: Alzheimer's